article thumbnail

Reinventing the small molecule toolbox: from proteins to RNA

Dark Matter Blog

Prior to 2015, I had a casual relationship, at best, with targeting RNA. The bulk of my nearly three decades of experience up to that point was with drugging protein targets using a variety of modalities, but principally small molecules. But do those hits bind the same structures in the wild?

article thumbnail

Lead Pharma Teams with Roche on Oral Small Molecules for Immune-Mediated Diseases

The Pharma Data

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The power of combinations in blood cancers

Drug Target Review

These regimens frequently include one or two small molecule inhibitors and immuno-oncology (IO) therapies, such as monoclonal antibodies and T-cell engagers. 2015);126(1):9-16. 2015);126(4):454-462. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.

article thumbnail

Got It Down Cold: Cryo-Electron Microscopy Named Method of the Year

NIH Director's Blog: Drug Discovery

Very impressive, and just one of the many reasons why the journal Nature Methods recently named cryo-EM its “Method of the Year” for 2015 [2]. Cryo-EM maps showing the contacts between small molecules and proteins can help to explore questions such as why one drug is better than another or why certain drugs fail. Nature Methods.

article thumbnail

Fearlessly Forward to our Destination

Dark Matter Blog

Our terra firma is small-molecule medicines. As we know, small molecules have been the mainstay of our pharmacopeia for several centuries and have, almost without exception, targeted proteins. This is why Arrakis set out in 2015 on an expedition to figure out how to develop small molecules that can target RNA.

article thumbnail

Sosei Heptares scores $5m milestone payment from Pfizer

The Pharma Data

The collaboration has leveraged Sosei’s StaR technology and Structure-based Drug Design (SBDD) capabilities to design oral small molecules that modulate different G protein-coupled receptor (GPCR) targets across multiple disease areas. At the time, Pfizer made a $33m equity investment in Sosei as part of the collaboration agreement.

article thumbnail

Navigating the partnering galaxy

Dark Matter Blog

Since our company’s founding in 2015, we have taken the long view and been singularly focused on building an extremely flexible and broadly applicable platform that can develop a host of RNA‑targeted small molecules (rSMs) to deliver precision medicines for dozens of targets that have been out of reach for conventional approaches.